Correction to: Adv Ther (2020) 37:3732–3745 https://doi.org/10.1007/s12325-020-01437-4

In the original article, under the “Access to treatment” heading, there are incorrect text as” “Similarly, Razanskaite et al. [51] demonstrated that at the same time that costs were reduced following IFX biosimilar introduction, the number of treatments went up from a maximum of 100,000 vials/month to 140,000 vials/month.” The correct text is as follows “Similarly, Razanskaite et al. [51] demonstrated that at the same time that costs were reduced following IFX biosimilar introduction, the number of treatments went up from a maximum of ~ 350 vials/month to ~ 450 vials/month.”